ArticleiScience2026
Prenatal bisphenol A exposure reprograms SF1-lactylation pathways to promote endometriosis susceptibility.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is an estrogen-dependent disorder influenced by dysregulated steroidogenesis, oxidative stress, and inflammation. Bisphenol A (BPA), a common endocrine disruptor, has been associated with reproductive dysfunction, but its developmental impacts are unclear. We investigated whether prenatal BPA exposure induces lasting endocrine and epigenetic reprogramming that increases endometriosis susceptibility. In human endometrial stromal cells, BPA elevated histone lactylation, SF1, and CYP19A1 expression, oxidative stress, mitochondrial impairment, and inflammatory signaling. In a prenatal BPA mouse model, adult female offspring exhibited increased endometriosis-like lesions and reduced fertility. Pharmacologic inhibition of glycolytic lactate production or SF1 signaling (NaOx, AC45594) partially reversed these outcomes. These findings show that prenatal BPA drives persistent SF1-linked estrogenic activation and lactylation, promoting endometriosis risk and suggesting targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.